NORWOOD, Mass--A new implantable pump with an inexhaustible power
supply and a constant flow feature may allow lower morphine doses
in patients with cancer pain.
Infusaid Model 400, a single catheter implantable pump from Strato/Infusaid
Inc., a subsidiary of Pfizer Inc., has received FDA approval for
the intrathecal infusion of Infumorph (preservative-free morphine)
for treatment of severe and prolonged malignant and nonmalignant
pain in patients who do not respond to conventional treatment
The constant flow feature allows a continuous low-dose infusion
of drug into the epidural or intrathecal space.
The pump is powered by a two-phase charging fluid that liquefies
when the drug reservoir is filled. The drug is dispensed as the
charging fluid changes to a vapor state. Thus the Infusaid Model
400 never needs programming, recharging, or explantation due to
battery depletion, the company said.
Priced at about $5,000, the Infusaid Model 400 may be less expensive
than current alternatives. The manufacturer estimates total treatment
cost at 6 months of about $18,600 with Infusaid, compared to an
estimated $21,000 for implantable programmable pumps, $31,000
for implanted catheters, and $38,000 for externalized systems.
Any such cost advan-tages would increase as patient survival lengthens,
the company said. At 4 years, for example, treatment cost with
Infusaid would be about $35,000, compared with an estimated $274,000
for treatment with an externalized system.